Identification and characterization of new anti-angiogenic compounds from natural sources
| dc.centro | Facultad de Ciencias | es_ES |
| dc.contributor.author | Carrillo Fernández, Paloma | |
| dc.contributor.author | Ocaña Farfán, María del Carmen | |
| dc.contributor.author | Martínez-Póveda, Beatriz Amparo | |
| dc.contributor.author | Medina-Torres, Miguel Ángel | |
| dc.contributor.author | Rodríguez-Quesada, Ana María | |
| dc.date.accessioned | 2017-07-21T07:25:16Z | |
| dc.date.available | 2017-07-21T07:25:16Z | |
| dc.date.created | 2017 | |
| dc.date.issued | 2017-07-21 | |
| dc.departamento | Biología Molecular y Bioquímica | |
| dc.description.abstract | The inhibition of angiogenesis has attracted broad attention in the field of pharmacological research, not only for cancer, but for other angiogenesis dependent diseases including ophthalmic, cutaneous and inflammatory diseases, as well as a number of rare diseases. Our research group has characterized multiple new natural bioactive compounds with multitargeted antiangiogenic effects by employing a well-established set of in vitro, in vivo and ex vivo preclinical models of angiogenesis. Most of them have been isolated from plants and terrestrial microorganisms, mainly due to their higher availability and because their therapeutic effects had been previously known in folk traditional medicines. In vitro primary screening includes cell differentiation and toxicity and proliferation assays. Secondary screening involves several experiments to evaluate effects on adhesion, migration, invasion, apoptosis or cell cycle analysis, among others. Additionally, we perform a further molecular characterization analyzing possible signaling pathways that are affected to elucidate their mechanism of action. The characterization is completed with the ex vivo aortic ring assay, and in vivo assays, as CAM and zebrafish assays, to ensure the anti-angiogenic ability. As a fruit of the mentioned screening, a number of compounds with remarkable anti-angiogenic activity have been identified and characterized. | es_ES |
| dc.description.sponsorship | Our experimental work is supported by grants BIO2014-56092-R (MINECO and FEDER) and P12-CTS-1507 (Andalusian Government and FEDER) and funds from group BIO-267 (Andalusian Government). The "CIBER de Enfermedades Raras" is an initiative from the ISCIII (Spain)]. This communicaction has the support of a travel grant "Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech". | es_ES |
| dc.identifier.orcid | http://orcid.org/000-0001-7275-6462 | es_ES |
| dc.identifier.uri | http://hdl.handle.net/10630/14305 | |
| dc.language.iso | eng | es_ES |
| dc.relation.eventdate | 22 de junio de 2017 | es_ES |
| dc.relation.eventplace | Trento, Italia | es_ES |
| dc.relation.eventtitle | 29th Pezcoller Symposium | es_ES |
| dc.rights | by-nc-nd | |
| dc.rights.accessRights | open access | es_ES |
| dc.subject | Neovascularización | es_ES |
| dc.subject.other | Angiogenesis | es_ES |
| dc.subject.other | Natural bio-active compounds | es_ES |
| dc.title | Identification and characterization of new anti-angiogenic compounds from natural sources | es_ES |
| dc.type | conference output | es_ES |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 796ec342-e395-494c-a22d-ce9adbad34d5 | |
| relation.isAuthorOfPublication | dddb6cd7-0e48-4c9d-82c7-d80fe8b23544 | |
| relation.isAuthorOfPublication | 64ecf6af-9938-4725-9539-659cb04fae88 | |
| relation.isAuthorOfPublication.latestForDiscovery | 796ec342-e395-494c-a22d-ce9adbad34d5 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Abstract trento.pdf
- Size:
- 55.63 KB
- Format:
- Adobe Portable Document Format
- Description:
- Resumen de la comunicación al simposio
Description: Resumen de la comunicación al simposio

